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referred for PFO closure between Oct. 2006 and july 2011 in the Toulouse
Rangueil universitary hospital. Follow-up data were available in May 2012.
Results: At baseline, all patients had dyspnea (58.3% NYHA 4). Eight
patients (33.3%) had a history of stroke attack. POS was related to right pneu-
monectomy in 3 patients (12.5%), ascending aortic ectasy in 11 patients
(45.8%), hepato-renal polycystic disease in 2 patients (8.3%). Aneurysm of
the inter-atrial septum was observed in 12 patients (50%). PaO2 was lower
in erect position compared to recumbent position (50.4±6.8 versus
72.6±12.5 mmHg, p=0.0005). Closure of the PFO was performed percutane-
ously in 24 patients (100%). An additional surgical PFO closure was neces-
sary in 1 patient because of significant residual shunting. PaO2 in erect
position was significantly increased after closure (p=0.0254).
During follow-up, 4 patients (16.7%, p=0.125) had a complete relief of
their symptoms after closure. Dyspnea was significantly improved according
to NYHA functional class (p=0.023). General status improved in 75% patients
(p=0.025). Eight patients died (33.3%). Four deaths (50%) were related to
stroke attacks at respectively 18 days, 3,11 and 39 months after PFO closure.
Four deaths were not related to cardiac issue.
Conclusion: Patients referred for PFO closure for POS are old and at high
risk of mortality, particularly from stroke attacks. PFO closure is associated
with an improvement of the functional NYHA class and of the general status.
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Bleeding and femoral access complications which occurred after balloon
aortic valvuloplasty (BAV) may be enhanced by the systematic use of heparin
during the procedure. We assessed the hypothesis that BAV performed
without heparin may be associated with lower complications rates.
Methods: We conducted a retrospective analysis of all consecutive
patients who had undergone BAV in our center between 2008 and 2011. We
evaluated 3 groups: group 1 included patients whose BAV was performed
with large sheaths (10 to 12 F) and use of unfractionated heparin (UH)
(50IU/kg bolus IV); patients whose BAV was performed with use of smaller
size sheaths (8 or 9 F) who were divided into group 2 (with UH bolus) and
group 3 (without UH bolus). We collected all major in-hospital adverse
events, bleeding (≥BARC 3), vascular complications (including pseudoan-
erysm or arterio venous fistula) and acute limb ischemia.
Results: Overall, 132 patients were included in this study. The 3 groups
had similar median age (84 years) or previous lower extremity artery disease
(overall n= 36, 27%, p=0.79). Vascular and bleeding complications were
observed in 17 patients (12.8%) and were significantly higher when UH was
used (table 1) with a relative risk of 2.89 (1.18-6.1). Conversely, absence of
heparin did not increase ischemic complications or major in-hospital adverse
events (p=0.5). Vascular complications were similar among patients who
received heparin whatever the size of the used sheath (table 1).
Conclusion: Balloon aortic valvuloplasty performed without heparin
appears to be safe and is associated with a dramatic reduction of vascular and
bleeding events. Although randomization was not used, this marked difference
is difficult to explain by confounding factors.
Table 1 – Vascular and bleeding complications
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Background: Few data are currently available about patients characteris-
tics and procedural features associated with AKI after TAVI using the new
recommended VARC definition.
Methods: 99 patients underwent TAVI (1 procedural death, 78.8% trans-
femoral, 12.1% trans-apical/aortic and 9.1% subclavian access) between Feb-
ruary 2009 and September 2011 at Rennes university hospital. Creatinine level
was assessed daily at least up to 72 hours after TAVI. Patients’ characteristics,
procedural features and outcomes according to VARC definitions were studied
to evaluate determinants and prognostic impact of AKI.
Results: AKI occurred in 22 patients (22.2%). Among them, 5 were AKI
2 (5.1%), 8 were AKI 3 (9.1%) including 4 who needed dialysis (4%). At
baseline, compared to no AKI or AKI 1, AKI 2 or 3 patients had a higher
prevalence of moderate or severe chronic kidney disease (p=0.046) and ≥
grade 2 mitral regurgitation (p=0.03). During the post TAVI hospitalization,
AKI 2 or 3 was associated to a higher rate of death from any cause
(p=0.0009), major bleeding, acute heart failure (both p=0.002), infectious
complications (p=0.0008) and longer total and ICU hospitalization duration
(p=0.0004 and <0.0001 respectively). AKI 2 or 3 patients had a higher rate of
30-days and 6 months death from any cause (p=0.005 and p=0.0002 respec-
tively) but only because of the deaths occurring during the initial hospitaliza-
tion. Only AKI 3 was associated with a higher risk of 6-months NYHA class
III or IV (p=0.016).
Conclusion: AKI 2 or 3 as defined by the VARC criteria were associated
with a higher risk of post procedural death because of their association with
other major post procedural complications. AKI 3 was associated with a
higher risk of short term worse functional outcomes.
group 1 
(UH+, LS) 
n=23 
group 2 
(UH+, SS) 
n=46 
group 3
 (UH-, SS) 
n=63 
p
value
Femoral access and/or 
bleeding n=17 (12.8%) 
4 (17.3%) 9 (19.5.%) 4 (6.3%)* 0.007
Bleeding n=15 (11.3%) 4 (17.3%) 8 (17.3%) 3 (4.7%)* 0.004
Acute limb ischemia n=4 
(2.2%)
0 2 (4.3%) 2 (3.1%) 0.82
UH+: unfractionated heparin bolus 50 ui/kg; UH-: no heparin bolus; 
LS: large sheath; SS: small sheath
o AKI or AKI 1
= 85
AKI 2 or 3
=13
p value
Age-yr
Logistic EuroSCORE
79.0 ±10.2
19.8±12.2
80.5±6.7
19.3±10.2
0.63
0.89
Left ventricular ejection fraction-%
Aortic valve area-cm²
48.2±14.4
0.68±0.15
58.1±12.5
0.71±0.22
0.02
0.56
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